The "Amyloid imaging to prevent Alzheimer’s disease" project aimed to improve the diagnostic workup of patients suspected to have Alzheimer's disease (AD) and their management. The partners aimed to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 115952. The JU receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.


Representatives of Alzheimer Europe involved in the project:

Alzheimer Europe Staff - Project Officer - Cindy Birck
Co-leadership of the Communication and Dissemination work package, ensuring that project activities and findings are shared with all stakeholders.